Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study

Introduction: Evaluation of the patients who present to the hospital with a complaint of chest pain or other signs suggestive of acute coronary syndrome (ACS) is time-consuming, expensive, and difficult. Most of the biochemical markers are negative in early phase acute myocardial ischemia. Recent li...

Full description

Bibliographic Details
Main Authors: Mehraj A Junedi, Abdulazim A Junaidi
Format: Article
Language:English
Published: Prathima Institute of Medical Sciences 2023-08-01
Series:Perspectives In Medical Research
Subjects:
Online Access:https://pimr.org.in/2023-vol11-issue-2/originalarticle4_v2.pdf
_version_ 1797449079894048768
author Mehraj A Junedi
Abdulazim A Junaidi
author_facet Mehraj A Junedi
Abdulazim A Junaidi
author_sort Mehraj A Junedi
collection DOAJ
description Introduction: Evaluation of the patients who present to the hospital with a complaint of chest pain or other signs suggestive of acute coronary syndrome (ACS) is time-consuming, expensive, and difficult. Most of the biochemical markers are negative in early phase acute myocardial ischemia. Recent literature reports have shown more interest in a new biochemical marker which is Ischemia-modified albumin for the detection of myocardial injury. Objective: to estimate the level of ischemia-modified albumin (IMA) as a risk factor for cardiovascular disease in diabetes mellitus patients. Materials and methods: A case-control study was undertaken with sixty Type-2 diabetic patients as cases and sixty non-diabetic healthy subjects as controls. Demographic data (sex, age), an ECG and Biochemical data were collected. Blood for IMA and HbA1C levels was collected within two hours of arrival, and IMA risk marker testing was performed before any heparin/thrombolytic treatment was started. Controlled and uncontrolled diabetic patients were determined by the level of their HBA1c and comparison with the means of IMA level in their serum. Results: The IMA was significantly increased in diabetic patients compared to healthy controls, with cut off value (0.92 IU/L), and there is also a significant increase in IMA level in uncontrolled diabetic patients (Mean ± SD; 240.55 + 52.5) that presented with acute chest pain and have signs and symptoms of cardiac ischemia when compared with the well-controlled diabetic patients(Mean ± SD; 159.8 ± 60.4). Conclusion: Ischemic Modified Albumin (IMA) level was elevated significantly in uncontrolled diabetic patients with early signs of early myocardial ischemia. Additionally, IMA estimation may improve our ability to identify ischaemic patients who are missed by current diagnostic strategies, or more confidently rule out patients who do not have ACS.
first_indexed 2024-03-09T14:19:39Z
format Article
id doaj.art-64ddc381b1f847529d7c77a1cd1c1179
institution Directory Open Access Journal
issn 2348-1447
2348-229X
language English
last_indexed 2024-03-09T14:19:39Z
publishDate 2023-08-01
publisher Prathima Institute of Medical Sciences
record_format Article
series Perspectives In Medical Research
spelling doaj.art-64ddc381b1f847529d7c77a1cd1c11792023-11-28T16:18:53ZengPrathima Institute of Medical SciencesPerspectives In Medical Research2348-14472348-229X2023-08-01112172210.47799/pimr.1102.0404Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control studyMehraj A Junedi0Abdulazim A Junaidi1Assistant professor, Department of Biochemistry, Ashwini Rural Medical College, Hospital & Research Centre, Kumbhari, Maharashtra, IndiaAssistant professor, Department of Biochemistry, Ashwini Rural Medical College, Hospital & Research Centre, Kumbhari, Maharashtra, IndiaIntroduction: Evaluation of the patients who present to the hospital with a complaint of chest pain or other signs suggestive of acute coronary syndrome (ACS) is time-consuming, expensive, and difficult. Most of the biochemical markers are negative in early phase acute myocardial ischemia. Recent literature reports have shown more interest in a new biochemical marker which is Ischemia-modified albumin for the detection of myocardial injury. Objective: to estimate the level of ischemia-modified albumin (IMA) as a risk factor for cardiovascular disease in diabetes mellitus patients. Materials and methods: A case-control study was undertaken with sixty Type-2 diabetic patients as cases and sixty non-diabetic healthy subjects as controls. Demographic data (sex, age), an ECG and Biochemical data were collected. Blood for IMA and HbA1C levels was collected within two hours of arrival, and IMA risk marker testing was performed before any heparin/thrombolytic treatment was started. Controlled and uncontrolled diabetic patients were determined by the level of their HBA1c and comparison with the means of IMA level in their serum. Results: The IMA was significantly increased in diabetic patients compared to healthy controls, with cut off value (0.92 IU/L), and there is also a significant increase in IMA level in uncontrolled diabetic patients (Mean ± SD; 240.55 + 52.5) that presented with acute chest pain and have signs and symptoms of cardiac ischemia when compared with the well-controlled diabetic patients(Mean ± SD; 159.8 ± 60.4). Conclusion: Ischemic Modified Albumin (IMA) level was elevated significantly in uncontrolled diabetic patients with early signs of early myocardial ischemia. Additionally, IMA estimation may improve our ability to identify ischaemic patients who are missed by current diagnostic strategies, or more confidently rule out patients who do not have ACS.https://pimr.org.in/2023-vol11-issue-2/originalarticle4_v2.pdfacute coronary syndrome (acs)ischemia-modified albumin (ima)biomarkerdiabetes mellitus
spellingShingle Mehraj A Junedi
Abdulazim A Junaidi
Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study
Perspectives In Medical Research
acute coronary syndrome (acs)
ischemia-modified albumin (ima)
biomarker
diabetes mellitus
title Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study
title_full Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study
title_fullStr Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study
title_full_unstemmed Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study
title_short Ischemia-Modified Albumin (IMA) for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus: a case control study
title_sort ischemia modified albumin ima for early detection of myocardial ischemia in acute coronary syndrome with type 2 diabetes mellitus a case control study
topic acute coronary syndrome (acs)
ischemia-modified albumin (ima)
biomarker
diabetes mellitus
url https://pimr.org.in/2023-vol11-issue-2/originalarticle4_v2.pdf
work_keys_str_mv AT mehrajajunedi ischemiamodifiedalbuminimaforearlydetectionofmyocardialischemiainacutecoronarysyndromewithtype2diabetesmellitusacasecontrolstudy
AT abdulazimajunaidi ischemiamodifiedalbuminimaforearlydetectionofmyocardialischemiainacutecoronarysyndromewithtype2diabetesmellitusacasecontrolstudy